High-grade gliomas may be able to wire themselves into the healthy brain, receiving and interpreting electrical signals from normal neurons.
This week in industry includes trials on elenbecestat to be discontinued, ofatumumab demonstrating superiority to Aubagio and the Toca 5 trial results failing to meet primary endpoint.
New research has revealed that gliomas in neurofibromatosis type 1 (NF1) patients may be effectively treated by immunotherapy.
Researchers have made progress in developing liquid biopsies for brain tumors by detecting tumor DNA in the cerebrospinal fluid of glioma patients.
A large, multicenter, genome-wide association study has identified a number of new genetic risk loci for malignant brain tumors.
New research has elucidated a pathway in diffuse intrinsic pontine glioma with promise for therapeutic targeting.
Christian Naus discusses his work on 3D glioma models, which could facilitate personalized medicine approaches to one of the brain’s most significant threats.
A recent study has identified a potential genetic biomarker, SHOX2, for predicting the survival of patients with diffuse glioma brain tumors.
Researchers have developed novel mini ‘artificial brains’ to model glioma tumor growth: the organoids could soon be used to develop personalized treatment strategies against brain cancers.
This review selectively highlights presentations from this meeting in an organizational manner that reflects clinically relevant aspects of a large and multifaceted meeting.